shares of Horizon Therapeutics PLC (HZNP) on
Horizon Therapeutics Plc is a biopharmaceutical company, which is engages in the research, development, and marketing of pharmaceutical products. The company is headquartered in Dublin, Dublin and currently employs 1,175 full-time employees. The firm is focused on researching, developing and commercializing medicines that address needs for people impacted by rare and rheumatic diseases. The firm markets approximately 10 medicines, of which 6 are for rare and rheumatic diseases. The firm’s marketed medicines are ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS (ibuprofen/famotidine), KRYSTEXXA (pegloticase), PENNSAID (diclofenac sodium topical solution) 2% weight per weight (w/w), or PENNSAID 2%, PROCYSBI (cysteamine bitartrate) delayed-release capsules, QUINSAIR (aerosolized form of levofloxacin), RAVICTI (glycerol phenylbutyrate) Oral Liquid, RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium).